SCHEMBL12059072

SCHEMBL12059072

CCCC(CC(C)C)N(C)C

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.33
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15267362 1.00 MAOB (0.33) MAOBTSHR
SCHEMBL23447101 0.82 TSHR (0.40) TSHR
SCHEMBL13995988 0.80 MAOB (0.39) MAOBTSHR
SCHEMBL3361400 0.80 TSHR (0.32) TSHR
SCHEMBL19686168 0.79 TSHR (0.31) TSHR
SCHEMBL11793548 0.79
SCHEMBL19397686 0.78 MAOB (0.35) MAOBTSHR
SCHEMBL19397681 0.78 MAOB (0.35) MAOBTSHR
SCHEMBL14175019 0.78 MAOB (0.35) MAOBTSHR
Hydrochloric Acid SCHEMBL30591305 0.77 TSHR (0.30) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022074391-A1 COMPOUNDS INHIBITORS OF METTL3 STORM THERAPEUTICS LIMITED (GB) 2022-04-14 WO disclosed
US-11072634-B2 Inhibitors of transglutaminases ZEDIRA GMBH (DE) 2021-07-27 US disclosed
US-20190322700-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2019-10-24 US disclosed
EP-2791137-B1 PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION PROCESS THEREFOR AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2019-01-23 EP disclosed
US-8318981-B2 Imidate compound and use thereof for pest control SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-11-27 US disclosed
US-8318981-B2 Imidate compound and use thereof for pest control SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-11-27 US disclosed
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof SUNOVION PHARMACEUTICALS INC. (US) 2011-12-29 US disclosed
US-20100210683-A1 IMIDATE COMPOUND AND USE THEREOF FOR PEST CONTROL SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2010-08-19 US disclosed
US-20100210683-A1 IMIDATE COMPOUND AND USE THEREOF FOR PEST CONTROL SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof GRM5, GRM2, GRM1 MAOB 2195/4885TSHR 1410/4885
US-20100210683-A1 IMIDATE COMPOUND AND USE THEREOF FOR PEST CONTROL CYP1A1, CYC1, C1S MAOB 480/4885TSHR 553/4885
US-20190322700-A1 INHIBITORS OF TRANSGLUTAMINASES TGM2, TGM3, TGM1 MAOB 433/4885TSHR 3246/4885
US-11072634-B2 Inhibitors of transglutaminases TGM2, TGM3, TGM1 MAOB 433/4885TSHR 3246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.